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Abstract: Nonthyroidal illness (NTI), often observed in critically ill
patients, arises through diverse alterations in the hypothalamus-
pituitary-thyroid (HPT) axis. However, the causal relationship between
underlying disease and NTI diversity in critically ill patients is poorly
understood.
The aim of this study was to examine NTI severity and adverse
outcomes in critically ill patients with respect to their underlying
disease(s).
The medical records of 616 patients admitted to the intensive care
unit (ICU) between January 2009 and October 2014 were retrospec-
tively reviewed. Patients with known diseases or takingmedications that
affect thyroid function were excluded. All-cause mortality (ACM) and
length of stay (LOS) in the ICU were assessed as adverse outcomes.
The enrolled patients (n¼ 213) were divided into the following 4
groups according to the severity of NTI at the nadir of their thyroid
function test (TFT): normal (n¼ 11, 5.2%), mild NTI (n¼ 113, 53.1%),
moderate NTI (n¼ 78, 36.6%), and severeNTI (n¼ 11, 5.2%). Therewas
no significant difference between the groups in terms of age and gender.
NTI severity showed a significantly strong association with ACM
(P< 0.0001) and a significant positive association with LOS in the
ICU (P¼ 0.031). After adjusting for age, gender, and current medications
affecting TFT, increasing NTI severity led to increased ACM (oddsg, MD, PhD, Eun hD,
Young Suk Jo, MD, PhD
(P¼ 0.012). Consistent with this, serum C-reactive protein levels were
higher in patients with moderate-to-severe NTI (P¼ 0.016).
NTI severity is associated with increased ACM, LOS, and underlying
infectious disease. Future studies will focus on the biological and clinical
implications of infectious disease on the HPT axis.
(Medicine 95(14):e3346)
Abbreviations: ACM = all-cause mortality, CRP = C-reactive
protein, D1 = type 1 deiodinase, D3 = type 3 deiodinase, ESR =
erythrocyte sedimentation rate, fT3 = free triiodothyronine, fT4 =
free thyroxine, GHRH = growth hormone-releasing hormone,
HPT = hypothalamus-pituitary-thyroid axis, ICU = intensive care
unit, IFN-g = interferon-gamma, IL-1 = interleukin-1, IL-6 =
interleukin-6, LOS = length of stay, NTI = non-thyroidal illness,
rT3 = reverse triiodothyronine, T3 = triiodothyronine, T4 =
thyroxine, TFT = thyroid function test, TNF-a = tumor necrosis
factor-alpha, TRH = thyrotropin-releasing hormone, TSH =
thyrotropin or thyroid-stimulating hormone.
INTRODUCTION
N onthyroidal illness (NTI) syndrome, also known as ‘‘sickeuthyroid syndrome’’ or ‘‘low T3 syndrome,’’ can be
described as variations in the results of thyroid function tests
(TFTs) in the absence of hypothalamic-pituitary and thyroid
gland dysfunction. The early adaptive stage of NTI usually
presents as low triiodothyronine (T3) or thyroxine (T4) levels,
without an increase in thyrotropin (TSH). In a clinical setting,
NTI is frequently observed in patients with acute or chronic
critical illnesses who require treatment in the intensive care unit
(ICU).1–4 However, the pathophysiology of NTI is unclear.
During the acute phase of critical illness (e.g., postsurgery
or severe physical stress), circulating levels of T3 fall rapidly.
These changes are generated by reduced levels of thyroid
hormone binding proteins such as thyroxine binding globulin
and albumin; thyroid hormone is easily released from thyroid
hormone binding proteins due to a reduction in their binding
affinity, leading to incremental increases in the clearance of
thyroid hormone.5 In addition, alterations in the peripheral
conversion of T4, mainly due to decreased type-1 deiodinase
(D1) activity and increased type-3 deiodinase (D3) activity,
induce the generation of reverse (r)T3.6,7 Although all these
changes reduce circulating T3 levels, plasma TSH concen-
trations usually remain normal.4
During a prolonged phase of critical illness, central
suppression of the hypothalamus-pituitary-thyroid (HPT) axis
occurs.8 As hypothalamic stimulation of the pituitary thyro-e production and release of thyroid
reduced; this can resemble central
terized by low plasma levels of unbound
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T4 and/or low TSH concentrations. At this stage, pulsatile
TSH secretion is almost abrogated.9 However, the mechanism
underlying NTI progression from an adaptive response to a
noncompensatory or maladaptive process that triggers hypo-
thalamic suppression is poorly understood.3
Recent studies suggest that cytokines such as tumor necro-
sis factor-alpha (TNF-a), interferon-gamma (IFN-g), interleu-
kin (IL)-1, and IL-6 are potential mediators of NTI. These
cytokines directly downregulate various components of
the thyroid hormone synthesis pathway at the thyrocyte
level10–16; however, no study has examined the role of cyto-
kines in NTI progression in large human cohorts.
Because NTI in patients with a critical illness could be
either adaptive or maladaptive,17 NTI during the acute phase of
critical illness is beneficial; however, it may be deleterious
during the prolonged phase. The latter interpretation stems from
the observation that changes in plasma thyroid hormone levels
are related to the risk of adverse outcomes.18–20 Here, we
Lee et alexamined the correlation between NTI severity and adverse
outcomes. In addition, we investigated NTI severity with
respect to underlying disease.
METHODS
Study Population
The medical records of 616 patients admitted to the
medical and surgical ICU at Severance Hospital, Yonsei College
of Medicine (Seoul, South Korea) between January 2009 and
October 2014 were retrospectively reviewed. All patients under-
went a TFT (T3, fT4, TSH) while being treated in the ICU.
Of the 616 patients, 403 were excluded under the following
exclusion criteria: patients had subclinical or clinical thyrotoxi-
cosis/hypothyroidism before admission to the ICU21; patients
had pre-existing thyroid or pituitary-hypothalamic disease;
patients had liver or renal disease, such as liver cirrhosis,
nephrotic syndrome, and renal failure; patients had brain injury
or surgery for brain tumor; or patients were taking levothyrox-
ine, thyrostatic agents, or drugs that affect thyroid function (e.g.,
amiodarone, lithium, glucocorticoid, salicylates, furosemide,
ferrous sulfate, phenytoin, carbamazepine, or phenobarbital).
Finally, 213 patients, 202 with NTI (32.8%) and 11 with normal
thyroid function (1.8%), were included in the study. The 202
NTI patients were divided into 3 groups according to NTI
severity as previously proposed by a textbook22: mild NTI
(n¼ 113), moderate NTI (n¼ 78), and severe NTI (n¼ 11)
(Supplementary Table 1, http://links.lww.com/MD/A888).
The study was approved by the Institutional Review Board,
which waived the requirement for informed consent because of
the retrospective design of the study.
TFT, Biochemical Measurements, and Acute
Inflammatory Indices
All blood samples were obtained after fasting patients for
12 hours. Serum-bound T3, free T4, and TSH were measured
in a chemiluminescent microparticle immunoassay (Architect
System; Abbott Ireland Diagnostic Division, Lisnamuck, Long-
ford, Co. Longford, Ireland). The reference ranges were as
follows: 0.58 to 1.59 ng/dL for bound T3, 0.70 to 1.48 ng/dL for
free T4, and 0.35 to 4.94mIU/mL for TSH. The most severe
TFT results were analyzed. Serum total protein and albumin
levels were measured using the Hitachi 7600 DDP analyzer
(Hitachi High Technologies Co., Tokyo, Japan). Serum
C-reactive protein (CRP) concentrations were measured using
2 | www.md-journal.coma nephelometric method (Beckman Coulter, Fullerton, CA). The
erythrocyte sedimentation rate (ESR) was assessed using the
Westergren method (Alifax, Padova, Italy). The reference ranges
were as follows: 6 to 8 g/dL for total protein, 3.3 to 5.3 g/dL for
albumin, 0 to 8mg/L for CRP, and 0 to 20mm/hour for ESR.
Diagnosis of Underlying Disease, Patient
Outcome, and Drugs as Confounders
The main diagnoses upon admission to the ICU were
recorded for analysis. In terms of patient outcome, all-cause
mortality (ACM) and the length of stay (LOS) in the ICU were
examined. Initiation of levothyroxine, hypothalamic-releasing
factor, thyrostatic agent, dopamine, amiodarone, or steroid
treatment in the ICU was also examined to determine whether
NTI severity is an independent risk factor for a poor outcome.
Statistical Analysis
Continuous variables were compared using either the 2-
tailed Student t test or analysis of variance (ANOVA) test, and
categorical data were compared using either a 2-tailed x2 test or
Fisher’s exact test. The relationship between NTI severity and
ACM was analyzed using a multivariate logistic regression
model adjusted for age, gender, and the use of drugs that can
affect thyroid function. Pearson’s correlation coefficient was
used to examine the association between thyroid hormone levels
and acute inflammatory indices. Statistical analyses were per-
formed using Statistical Package for the Social Sciences (SPSS)
software for Windows (Version 21.0; IBM Corp., NY) or
GraphPad Prism (GraphPad Software, Inc., San Diego, CA).
P value less than 0.05 was considered statistically significant.
RESULTS
Baseline Patient Characteristics
The baseline characteristics of the 213 patients with
normal thyroid function or NTI are listed in Table 1. Of these,
11 had normal thyroid function and the other 202 had NTI,
classed as mild (n¼ 113, 55.9%), moderate (n¼ 78, 38.6%), or
severe (n¼ 11, 5.4%). There was no significant difference
between the groups with respect to age and gender. As expected,
NTI severity was closely related to T3, fT4, and TSH values
(P< 0.0001). In addition,NTI severity also correlatedwith serum
total protein (P< 0.0001) and albumin (P¼ 0.002) levels.
Association Between NTI Severity and Patient
Outcome
We next examined the relationship between NTI severity
and ACM and LOS. NTI severity was strongly associated with
ACM (P< 0.0001; Figure 1A). In particular, ACM for patients
with moderate or severe NTI was significantly higher than that
for patients with mild NTI (P¼ 0.001; Figure 1A). LOS in the
ICU was also related to NTI severity (P¼ 0.031; Figure 1B). To
determine whether NTI is an independent risk factor for ACM,
we used a multivariate logistic regression model adjusted for
age, gender, and use of drugs that can affect thyroid function
(such as dopamine, amiodarone, and steroids). Patients were
split into 2 groups: Group I contained patients with normal or
mild NTI, and Group II contained patients with moderate or
severe NTI. According to model 1 (adjusted for age and gender),
the risk of ACMwas significantly higher in Group II [odds ratio
Medicine  Volume 95, Number 14, April 2016(OR)¼ 3.519; 95% confidence interval (95% CI)¼ 1.975–
6.271; P< 0.0001; Table 2]. According to model 2 (adjusted
for age, gender, and the use of drugs that can affect thyroid
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TABLE 1. Baseline Characteristics of the Study Population
Variable Normal (n¼ 11) Mild NTI (n¼ 113) Moderate NTI (n¼ 78) Severe NTI (n¼ 11) P
Age, y 58.9 17.4 69.1 15.6 66.9 15.2 64.0 14.2 0.155
Gender, n (% female) 4 (36.4) 55 (48.7) 29 (37.2) 5 (45.5) 0.437
T3, ng/mL 0.76 0.13 0.38 0.15 0.32 0.18 0.21 0.17 <0.0001
fT4, ng/dL 1.12 0.21 0.99 0.19 0.94 0.24 0.56 0.19 <0.0001
TSH, mIU/mL 1.55 1.16 1.50 1.06 0.40 0.79 0.11 0.12 <0.0001
Total protein, g/dL 4.96 0.99 4.52 0.85 4.23 0.80 3.67 0.48 <0.0001
Albumin, g/dL 2.51 0.81 2.18 0.40 2.11 0.48 1.78 0.20 0.002
Data are expressed as meanSD or as n (%).
atio
oto
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again higher for Group II (OR¼ 3.101; 95% CI¼ 1.711–5.618;
P< 0.0001; Table 2).
NTI Severity and Infection
Because we observed a positive correlation between NTI
severity and ACM and LOS, we next investigated the relation-
ship between NTI and the underlying diseases that caused
patients to be admitted to the ICU. NTI was more severe in
patients with infectious diseases such as pneumonia and infec-
tions of nonlung origin (Table 3). To examine the effect of
infection on NTI severity, we sorted the study patients into 2
groups: those with infectious disease and those with noninfec-
tious disease (n¼ 75 and n¼ 138, respectively). There was a
significant difference in CRP levels between those with infec-
tious disease and those with noninfectious disease, indicating
that the sorting was conducted appropriately (Supplementary
Table 2, http://links.lww.com/MD/A888). The percentage of
patients with moderate or severe NTI was significantly higher in
the infectious disease group (P¼ 0.012); in particular, severe
NTI was only observed in the infectious disease group
(Figure 2).
Association Between NTI Severity and Acute
fT4¼ free thyroxine, NTI¼ nonthyroidal illness, SD¼ standard devi
Continuous variables were analyzed using 1-way ANOVA and dichInflammatory Indices
To verify the relationship between NTI severity and
infectious disease, we examined the relationship between
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FIGURE 1. Relationship betweenNTI severity and patient outcome. (A
all-cause mortality (ACM). (B) The length of stay (LOS) in the ICU
relationship between NTI severity and ACM and LOS was examined
respectively. Error bars represent the standard error. ICU¼ intensive c
determined between the four groups.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.NTI severity and acute inflammatory indices such as CRP
levels and the ESR. CRP levels tended to increase according
to NTI severity (P¼ 0.045; Figure 3A, upper panel). In
addition, CRP levels were significantly higher in NTI group
II than in NTI group I (P¼ 0.016; Figure 3A, lower panel). By
contrast, there was no significant difference in ESR levels
between the 2 groups. CRP levels in the infectious disease
group also tended to increase with NTI severity, although the
difference was not statistically significant (Supplementary
Figure 1, http://links.lww.com/MD/A888). Finally, we per-
formed bivariate correlation analysis to explore the correlation
between thyroid hormone and CRP levels, and found that T3
levels negatively correlated with CRP levels (r¼0.199;
P¼ 0.004; Figure 3B).
DISCUSSION
This cohort study examined the association between NTI
severity and patient outcome (ACM and LOS in the ICU). In
addition, to understand the relationship between NTI severity
and underlying disease, we also examined the etiology under-
lying NTI in our study patients. NTI severity was associated
with an increased risk of an adverse outcome; the correlation
remained statistically significant even after adjusting for iatro-
genic drug interference. NTI was more severe in the group with
n, T3¼ triiodothyronine, TSH¼ thyroid-stimulating hormone.
mous variables were analyzed using Fisher’s exact test.infectious disease than in the group with noninfectious disease;
moreover, CRP levels were significantly higher in those with
more severe NTI. These findings suggest that NTI severity is an
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) The severity of NTI was significantly associated with an increase in
tended to be longer in the moderate-to-severe NTI group. The
using the Chi-square test/Fisher’s exact test and 1-way ANOVA,
are unit; NTI¼nonthyroidal illness. P¼0.001. P for trend was
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TABLE 2. Relationship Between NTI Severity and All-Cause Mortality After Adjusting for Confounders
Model 1 Model 2
OR (95% CI) P OR (95% CI) P
Age 1.009 (0.991–1.028) 0.320 1.012 (0.993–1.031) 0.223
Gender (female) 0.721 (0.406–1.281) 0.265 0.710 (0.396–1.272) 0.249
NTI (moderate and severe)

3.519 (1.975–6.271) <0.0001 3.101 (1.711–5.618) <0.0001
Amiodarone 0.707 (0.103–4.866) 0.725
Dopamine 0.786 (0.234–2.642) 0.697
Steroid 1.800 (0.988–3.279) 0.055
Model 1: Adjusted for age and gender.
Model 2: As model 1 and adjusted for the use of drugs that can affect thyroid function.
There were no patients who received levothyroxine, hypothalamic-releasing factors, or thyrostatic agents during their stay at the ICU.
dal
Lee et al Medicine  Volume 95, Number 14, April 2016independent risk factor for an adverse outcome for critically ill
patients, and that infectious diseases play a role in the devel-
opment of moderate-to-severe NTI. To the best of our knowl-
edge, this is the first population-based cohort study to examine
patient outcomes with respect to NTI severity, and the asso-
ciation between NTI severity and infection in critically ill
patients.
NTI is an adaptive response that occurs during the acute
phase of a critical illness; however, it can be deleterious during a
prolonged critical illness. As mentioned previously, during the
acute phase of a critical illness, circulating T3 levels fall rapidly,
accompanied by an acute rise in rT3. These changes mainly
result from changes in the circulation and peripheral organs
such as reduced thyroid hormone binding and increased inac-
tivation of thyroid hormones by type-3 deiodinases. Meanwhile,
during the prolonged phase, central suppression of the HPT axis
occurs. Here, we found that the more severe the NTI, the lower
CI¼ confidence interval, ICU¼ intensive care unit, NTI¼ nonthyroi
NTI (normal and mild) is a reference category.the total protein and albumin levels. Moreover, serum T3 levels
were positively correlated with plasma protein and albumin
levels (Supplementary Figure 2, http://links.lww.com/MD/
TABLE 3. NTI Severity According to Underlying Disease
Diseasey
Patients
(n)
Gender
(%Female)
Ag
Pneumonia 79 39.2 69.4
Infection of nonlung origin 59 47.5 63.9
Malignancy 18 44.4 66.8
Gastrointestinal disease 5 60.0 76.0
Cardiac disease 3 0.0 74.0
Renal disease 6 50.0 76.7
Lung disease 8 75.0 73.4
Bleeding 9 33.3 68.0
CNS disease 10 45.5 67.4
Transplantation 5 40.0 56.8
Otherz 11 45.5 64.6
CNS¼ central nervous system, NTI¼ nonthyroidal illness, SD¼ standar
Data are expressed as meansSD.
yBased on the main diagnosis when patients were admitted to the intens
zAmyotrophic lateral sclerosis, aplastic anemia, autoimmune hepatitis, di
(n¼ 2), pyoderma gangrenosum, toxic epidermal necrolysis, and trauma.
4 | www.md-journal.comA888). These results indicate that reduced thyroid hormone
binding (due to reduced protein and albumin levels) plays a role
in the development of NTI; this condition is probably persistent,
even in cases of moderate or severe NTI involving
hypothalamic suppression.
A few studies exploring the relationship between NTI and
outcome in critically ill patients have been published.18,23–28
Two of these show that reduced fT4 levels are associated with
mortality independently of TSH levels,25,27 whereas others
found that T3 is a major predictor of survival.26,28 However,
all of these studies were conducted on small numbers of selected
patients. Here, we assessed thyroid function in 616 patients
admitted to the ICU, and examined the association between NTI
and outcomes in a final group of 202 patients with NTI; this is
one of the largest cohorts reported to date. To minimize the
effects of confounding factors, we excluded patients with
underlying liver or renal diseases because these diseases can
illness, OR¼ odds ratio.affect thyroid function directly by decreasing thyroid hormone
binding capacity or changing clearance, which can make the
severity of NTI worse than those caused by event-related
e

,
y
Normal,
%
Mild
NTI, %
Moderate
NTI, %
Severe
NTI, %
 15.0 5.1 44.3 40.5 10.1
 16.1 5.1 50.8 39.0 5.1
 15.2 5.6 55.6 38.9 0
 16.5 0 80.0 20.0 0
 12.5 0 100 0 0
 14.6 0 83.3 16.7 0
 13.1 0 62.5 37.5 0
 15.0 0 55.6 44.4 0
 15.5 0 70.0 30.0 0
 17.0 0 40.0 60.0 0
 17.0 27.3 63.6 9.1 0
d deviation.
ive care unit.
abetic foot, diabetic ketoacidosis, previa totalis, postresuscitation status
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patient outcome in specific clinical settings.19,20,29–32 For
example, Tognini et al reported that T3 levels are associated
with short-term survival in a hospitalized older population,20
and Meuwese et al reported that fT3 levels were negatively
associated with vascular calcification in patients with end-stage
renal disease.30 However, these results are not generalizable to
the association between NTI and critical illness. Furthermore,
few studies have examined patient outcome according to NTI
severity. Plikat et al reported that patients with low fT3 and fT4
levels had a higher mortality than patients with normal thyroid
FIGURE 2. NTI severity in patients with infectious disease and nonin
infectious disease than in those with noninfectious disease. Datafunction and low fT3 levels. However, additional reductions in
TSH levels, that is, severe NTI indicating central suppression of
the HPT axis, did not affect patient outcome, including
0
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Normal + Mild 
(n = 122) 
Moderate + Severe 
(n = 88) P-value 
CRP (mg/L) 196.80 ? 101.77 231.18 ? 99.48 0.016 
ESR(mm/hr) 80.26 ? 37.06 76.47 ?36.39 0.466 
A
FIGURE 3. Relationship between NTI severity and acute inflammato
inflammatory indices in the entire cohort. CRP levels increased signifi
moderate and severe NTI were compared with those in patients with
significantly higher in the former. However, therewere no significant dif
T3 and CRP levels. T3 levels were inversely correlated with CRP levels
ANOVA. A 2-sample t test was conducted to compare acute inflammat
normal and mild NTI group. Pearson’s correlation coefficient was used
error. Data in the tables are expressed as means SD. CRP¼C-reactive
illness; SD¼ standard deviation; T3¼ triiodothyronine.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.mortality.2 Here, we found that mortality was higher for patients
with severe NTI (90.9%) than for those with mild or moderate
NTI (37.2% and 61.5%, respectively), indicating that NTI
severity is an important risk factor for an adverse outcome in
critically ill patients.
Inflammatory cytokines are linked to the development of
NTI. According to several studies, IL-1a and IL-1b inhibit both
125I uptake and thyroid hormone secretion by human-cultured
thyrocytes in the presence of TSH.33 IL-6 also inhibits TSH-
induced increases in thyroid peroxidase mRNA expression and
T3 release by thyrocytes obtained from patients with Graves’
tious disease. NTI was significantlymore severe in the patients with
e examined using Fisher’s exact test. NTI¼nonthyroidal illness.disease.14 Furthermore, TNF-a and IFN-g directly downregu-
late several components of the thyroid hormone synthesis
pathway at the thyrocyte level.11,34,35 Also, thyroid hormone
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0
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1 .0
C R P (m g /L )
T
3
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/m
L
)
R = - 0 .1 9 9 , P = 0 .0 0 4
B
ry indices. (A) The relationship between NTI severity and acute
cantly with the severity of NTI. When CRP levels in patients with
normal thyroid function or those with mild NTI, CRP levels were
ferences in ESR levels between the groups. (B) Correlation between
(r¼0.199, P¼0.004). P for trend was determined by 1-way
ory indices in the moderate and severe NTI group with those in the
for bivariate correlation analysis. Error bars represent the standard
protein; ESR¼ erythrocyte sedimentation rate; NTI¼nonthyroidal
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levels in an animal model fell after the administration of
inflammatory cytokines.36 Accordingly, a few human studies
describe a negative relationship between IL-6 and fT3 levels.37–
39 Consistent with these previous reports, we found that NTI is
more severe in patients with infectious disease than in those
with noninfectious disease, and that NTI severity is significantly
associated with higher CRP levels, which are directly related to
IL-6 levels.20 Moreover, T3 levels inversely correlated with
CRP levels. However, this association lost significance when
analyzing patients with infectious disease, although the trend
was maintained. This might be because patients with infectious
disease have worse liver function than patients with other
diseases (possibly due to sepsis), which affects CRP levels.40
Overall, the present study supports the hypothesis that inflam-
matory cytokines, along with binding proteins and deiodinases,
play a pivotal role in the development of NTI as well as in the
crosstalk between NTI and infection.
There is much controversy surrounding the treatment of
patients with NTI. Previous studies used animal models to
examine the effect of treatment with thyroid hormones (T3
and T4) compared with treatment with releasing factors such as
thyrotropin-releasing hormone (TRH) or growth hormone-
releasing hormone (GHRH).41–43 These studies demonstrate
that during a prolonged critical illness, treatment with T3 or T4
does not increase plasma thyroid hormone levels, whereas
infusion of TRH increases plasma T3 and T4 levels. Further-
more, as the main cause aggravating NTI during a prolonged
phase of critical illness is central suppression of the HPT axis
rather than thyroidal capacity or changes in peripheral metab-
olism, treatment with hypothalamic-releasing factors such as
TRH or GHRH may be better and more rational than treatment
with thyroid hormones. However, few studies have investigated
the effect of treatment with hypothalamic-releasing factors on
patient outcomes in adequately powered randomized controlled
trial. With regard to treatment of NTI during an acute phase of
critical illness, underlying diseases have been treated without
thyroid hormone replacement therapy, as NTI is an adaptive
response to reduce energy expenditure by lowering T3 levels.3
According to our current treatment policy, which is based on
treatments reported in the relevant literature, we commonly
monitor the thyroid function of patients with NTI but without
performing thyroid hormone supplementation or treatments
with hypothalamic-releasing factors, while maintaining treat-
ment for the underlying disease. The present study showed that
NTI was more severe in patients with infectious disease, and
that patient outcomes were worse for patients with moderate or
severe NTI. Therefore, future studies should enroll patients with
infectious disease who have moderate-to-severe NTI and
examine the effect of treatment with hypothalamic-releasing
factors on patient outcomes.
One limitation of the present study is its retrospective and
observational design. This may lead to selection bias and the
presence of confounding factors, although iatrogenic drug
interference was excluded.
In conclusion, the severity of NTI is associated with
adverse outcomes for critically ill patients, even after excluding
confounding factors. Also, NTI is more severe in patients with
infectious disease, possibly due to the presence of pro-inflam-
matory cytokines. Future studies should focus on the biological
and clinical implications of infection with respect to the HPT
Lee et alaxis. Furthermore, the outcomes of patients with infectious
disease and moderate-to-severe NTI should be examined after
treatment with hypothalamic-releasing factors.
6 | www.md-journal.comREFERENCES
1. Boonen E, Van den Berghe G. Endocrine responses to critical
illness: novel insights and therapeutic implications. J Clin Endocrinol
Metab. 2014;99:1569–1582.
2. Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome
of patients with nonthyroidal illness syndrome in a medical intensive
care unit. Metabolism. 2007;56:239–244.
3. Van den Berghe G. Non-thyroidal illness in the ICU: a syndrome
with different faces. Thyroid. 2014;24:1456–1465.
4. Van den Berghe GH. Acute and prolonged critical illness are two
distinct neuroendocrine paradigms. Verh K Acad Geneeskd Belg.
1998;60:487–518.
5. Docter R, van Toor H, Krenning EP, et al. Free thyroxine assessed
with three assays in sera of patients with nonthyroidal illness and of
subjects with abnormal concentrations of thyroxine-binding proteins.
Clin Chem. 1993;39:1668–1674.
6. Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and
increased inactivation of thyroid hormone in tissues of critically ill
patients. J Clin Endocrinol Metab. 2003;88:3202–3211.
7. Rodriguez-Perez A, Palos-Paz F, Kaptein E, et al. Identification of
molecular mechanisms related to nonthyroidal illness syndrome in
skeletal muscle and adipose tissue from patients with septic shock.
Clin Endocrinol (Oxf). 2008;68:821–827.
8. Mebis L, Van den Berghe G. Thyroid axis function and dysfunction
in critical illness. Best Pract Res Clin Endocrinol Metab.
2011;25:745–757.
9. Van den Berghe G, de Zegher F, Veldhuis JD, et al. Thyrotrophin
and prolactin release in prolonged critical illness: dynamics of
spontaneous secretion and effects of growth hormone-secretagogues.
Clin Endocrinol (Oxf). 1997;47:599–612.
10. Bartalena L, Bogazzi F, Brogioni S, et al. Role of cytokines in the
pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol.
1998;138:603–614.
11. Rasmussen AK, Kayser L, Feldt-Rasmussen U, et al. Influence of
tumour necrosis factor-alpha, tumour necrosis factor-beta and inter-
feron-gamma, separately and added together with interleukin-1 beta,
on the function of cultured human thyroid cells. J Endocrinol.
1994;143:359–365.
12. Yamashita S, Kimura H, Ashizawa K, et al. Interleukin-1 inhibits
thyrotrophin-induced human thyroglobulin gene expression. J Endo-
crinol. 1989;122:177–183.
13. Nolte A, Bechtner G, Rafferzeder M, et al. Interleukin-1 beta (IL-1
beta) binds to intact porcine thyroid follicles, decreases iodide
uptake but has no effect on cAMP formation or proliferation. Horm
Metab Res. 1994;26:413–418.
14. Tominaga T, Yamashita S, Nagayama Y, et al. Interleukin 6 inhibits
human thyroid peroxidase gene expression. Acta Endocrinol
(Copenh). 1991;124:290–294.
15. Ajjan RA, Watson PF, Findlay C, et al. The sodium iodide
symporter gene and its regulation by cytokines found in autoimmunity.
J Endocrinol. 1998;158:351–358.
16. Tang KT, Braverman LE, DeVito WJ. Tumor necrosis factor-alpha
and interferon-gamma modulate gene expression of type I 5’-deiodinase,
thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells.
Endocrinology. 1995;136:881–888.
17. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal
illness syndrome. J Clin Endocrinol Metab. 1999;84:151–164.
0 0
Medicine  Volume 95, Number 14, April 201618. Peeters RP, Wouters PJ, van Toor H, et al. Serum 3,3 ,5 -
triiodothyronine (rT3) and 3,5,30-triiodothyronine/rT3 are prognostic
markers in critically ill patients and are associated with postmortem tissue
deiodinase activities. J Clin Endocrinol Metab. 2005;90:4559–4565.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
19. Bello G, Pennisi MA, Montini L, et al. Nonthyroidal illness
syndrome and prolonged mechanical ventilation in patients admitted
to the ICU. Chest. 2009;135:1448–1454.
20. Tognini S, Marchini F, Dardano A, et al. Non-thyroidal illness
syndrome and short-term survival in a hospitalised older population.
Age Ageing. 2010;39:46–50.
21. Kim YA, Park YJ. Prevalence and risk factors of subclinical thyroid
disease. Endocrinol Metab. 2014;29:20–29.
22. Melmed S, Polonsky KS, Larsen PR, et al. Williams Textbook of
Endocrinology. Elsevier Health Sciences. 2011.
23. Leon-Sanz M, Lorente JA, Larrodera L, et al. Pituitary-thyroid
function in patients with septic shock and its relation with outcome.
Eur J Med Res. 1997;2:477–482.
24. Silberman H, Eisenberg D, Ryan J, et al. The relation of thyroid
indices in the critically ill patient to prognosis and nutritional
factors. Surg Gynecol Obstet. 1988;166:223–228.
25. Slag MF, Morley JE, Elson MK, et al. Hypothyroxinemia in
critically ill patients as a predictor of high mortality. JAMA.
1981;245:43–45.
26. Maldonado LS, Murata GH, Hershman JM, et al. Do thyroid
function tests independently predict survival in the critically ill?
Thyroid. 1992;2:119–123.
27. Van den Berghe G, Baxter RC, Weekers F, et al. The combined
administration of GH-releasing peptide-2 (GHRP-2), TRH and
GnRH to men with prolonged critical illness evokes superior
endocrine and metabolic effects compared to treatment with GHRP-
2 alone. Clin Endocrinol (Oxf). 2002;56:655–669.
28. Loh KC, Eng PC. Prevalence and prognostic relevance of sick
euthyroid syndrome in a medical intensive care unit. Ann Acad Med
Singapore. 1995;24:802–806.
29. Anastasiou O, Sydor S, Sowa JP, et al. Higher thyroid-stimulating
hormone, triiodothyronine and thyroxine values are associated with
better outcome in acute liver failure. PLoS One. 2015;10:e0132189.
30. Meuwese CL, Olauson H, Qureshi AR, et al. Associations between
thyroid hormones, calcification inhibitor levels and vascular calcifi-
cation in end-stage renal disease. PLoS One. 2015;10:e0132353.
31. Han G, Ren J, Liu S, et al. Nonthyroidal illness syndrome in
Medicine  Volume 95, Number 14, April 201632. Yasar Z, Kirakli C, Cimen P, et al. Is non-thyroidal illness syndrome
a predictor for prolonged weaning in intubated chronic obstructive
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.pulmonary disease patients? Int J Clin Exp Med. 2015;8:10114–
10121.
33. Sato K, Satoh T, Shizume K, et al. Inhibition of 125I organification
and thyroid hormone release by interleukin-1, tumor necrosis factor-
alpha, and interferon-gamma in human thyrocytes in suspension
culture. J Clin Endocrinol Metab. 1990;70:1735–1743.
34. Nagayama Y, Izumi M, Ashizawa K, et al. Inhibitory effect of
interferon-gamma on the response of human thyrocytes to thyrotro-
pin (TSH) stimulation: relationship between the response to TSH
and the expression of DR antigen. J Clin Endocrinol Metab.
1987;64:949–953.
35. Kung AW, Ma L, Lau KS. The role of interferon-gamma in
lymphocytic thyroiditis: its functional and pathological effect on
human thyrocytes in culture. Clin Exp Immunol. 1992;87:261–265.
36. Papanicolaou DA. Euthyroid Sick Syndrome and the role of
cytokines. Rev Endocr Metab Disord. 2000;1:43–48.
37. Murai H, Murakami S, Ishida K, et al. Elevated serum interleukin-6
and decreased thyroid hormone levels in postoperative patients and
effects of IL-6 on thyroid cell function in vitro. Thyroid.
1996;6:601–606.
38. Kimura T, Kanda T, Kotajima N, et al. Involvement of circulating
interleukin-6 and its receptor in the development of euthyroid sick
syndrome in patients with acute myocardial infarction. Eur J
Endocrinol. 2000;143:179–184.
39. Abo-Zenah HA, Shoeb SA, Sabry AA, et al. Relating circulating
thyroid hormone concentrations to serum interleukins-6 and -10 in
association with non-thyroidal illnesses including chronic renal
insufficiency. BMC Endocr Disord. 2008;8:1.
40. Pepys MB, Hirschfield GM. C-reactive protein: a critical update.
J Clin Invest. 2003;111:1805–1812.
41. Debaveye Y, Ellger B, Mebis L, et al. Tissue deiodinase activity
during prolonged critical illness: effects of exogenous thyrotropin-
releasing hormone and its combination with growth hormone-
releasing peptide-2. Endocrinology. 2005;146:5604–5611.
42. Debaveye Y, Ellger B, Mebis L, et al. Regulation of tissue
iodothyronine deiodinase activity in a model of prolonged critical
illness. Thyroid. 2008;18:551–560.
Nonthyroidal Illness in Critically Ill Patients43. Debaveye Y, Ellger B, Mebis L, et al. Effects of substitution and
enterocutaneous fistulas. Am J Surg. 2013;206:386–392. high-dose thyroid hormone therapy on deiodination, sulfoconjuga-
tion, and tissue thyroid hormone levels in prolonged critically ill
rabbits. Endocrinology. 2008;149:4218–4228.
www.md-journal.com | 7
